These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 28100092)

  • 1. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
    Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
    Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability.
    Chu R; Hurwitz S; Tauhid S; Bakshi R
    BMC Neurol; 2017 Sep; 17(1):172. PubMed ID: 28874119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
    Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R
    PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Uddin MN; Lebel RM; Seres P; Blevins G; Wilman AH
    Mult Scler; 2016 Aug; 22(9):1133-43. PubMed ID: 26503237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
    Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
    J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.
    Bergsland N; Zivadinov R; Dwyer MG; Weinstock-Guttman B; Benedict RH
    Mult Scler; 2016 Sep; 22(10):1327-36. PubMed ID: 26541795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).
    Amann M; Andělová M; Pfister A; Mueller-Lenke N; Traud S; Reinhardt J; Magon S; Bendfeldt K; Kappos L; Radue EW; Stippich C; Sprenger T
    Neuroimage Clin; 2015; 7():43-52. PubMed ID: 25610766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
    Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
    Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of regional grey matter atrophy in multiple sclerosis.
    Eshaghi A; Marinescu RV; Young AL; Firth NC; Prados F; Jorge Cardoso M; Tur C; De Angelis F; Cawley N; Brownlee WJ; De Stefano N; Laura Stromillo M; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Geurts JJG; Vrenken H; Wottschel V; Leurs CE; Uitdehaag B; Pirpamer L; Enzinger C; Ourselin S; Gandini Wheeler-Kingshott CA; Chard D; Thompson AJ; Barkhof F; Alexander DC; Ciccarelli O
    Brain; 2018 Jun; 141(6):1665-1677. PubMed ID: 29741648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal changes of deep gray matter shape in multiple sclerosis.
    Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
    Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
    Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study.
    Bakshi R; Benedict RH; Bermel RA; Caruthers SD; Puli SR; Tjoa CW; Fabiano AJ; Jacobs L
    Arch Neurol; 2002 Jan; 59(1):62-8. PubMed ID: 11790232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.
    Rubin M; Pagani E; Preziosa P; Meani A; Storelli L; Margoni M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200271. PubMed ID: 38896808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls.
    Elkady AM; Cobzas D; Sun H; Seres P; Blevins G; Wilman AH
    Mult Scler Relat Disord; 2019 Aug; 33():107-115. PubMed ID: 31181540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of MRI T1 Hypointense Brain Lesions on Cerebral Deep Gray Matter Volume Measures in Multiple Sclerosis.
    Buyukturkoglu K; Mormina E; De Jager PL; Riley CS; Leavitt VM
    J Neuroimaging; 2019 Jul; 29(4):458-462. PubMed ID: 30892794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.